280 related articles for article (PubMed ID: 37544810)
1. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
2. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
[TBL] [Abstract][Full Text] [Related]
3. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
Montoya S; Thompson MC
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
[TBL] [Abstract][Full Text] [Related]
4. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
5. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
6. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
7. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA; Riches JC
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
[TBL] [Abstract][Full Text] [Related]
8. BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C; Thompson PA
Blood Adv; 2024 May; 8(9):2300-2309. PubMed ID: 38478390
[TBL] [Abstract][Full Text] [Related]
9. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
10. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
11. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
13. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
14. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
16. Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
Perutelli F; Montalbano MC; Boccellato E; Coscia M; Vitale C
Curr Opin Oncol; 2022 Nov; 34(6):757-767. PubMed ID: 35993294
[TBL] [Abstract][Full Text] [Related]
17. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
18. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
[TBL] [Abstract][Full Text] [Related]
19. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
Robak T; Witkowska M; Smolewski P
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
[TBL] [Abstract][Full Text] [Related]
20. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
